computed tomography-guided cryoablation for adrenal metastasis secondary to non-small-cell lung cancer

Background: computed tomography (ct)-guided ablation has been used to treat adrenal metastasis (am). however, the incidence of am secondary to non-small-cell lung cancer (nsclc) has not been investigated. objectives: to assess the clinical efficacy of ct-guided cryoablation for treating am secondary to nsclc. patients and methods: this retrospective study was performed among patients with am secondary to nsclc, undergoing ct-guided cryoablation in our hospital. the rates of complete ablation, local recurrence, local recurrence-free survival (rfs), systematic rfs, and overall survival (os) were also analyzed. results: thirty-four consecutive patients with am secondary to nsclc (16 cases of squamous cell carcinoma [scc] and 18 cases of adenocarcinoma) underwent cryoablation in our hospital. the primary complete ablation rates were 93.8% and 88.9% in the scc and adenocarcinoma groups, respectively (p = 1.000). moderate blood pressure increases were observed in 7/34 (20.6%) patients during cryoablation. the local recurrence of am was observed in five and three patients in the scc and adenocarcinoma groups, respectively (p = 0.551). the median local rfs was 22 months in all patients, and there was no significant difference in terms of the local rfs between the scc and adenocarcinoma groups (38 vs. 17 months) (p = 0.093). the median systematic rfs was 28 months in all patients, and the systematic rfs was significantly longer in the scc group as compared to the adenocarcinoma group (56 vs. 19 months) (p = 0.001). the median os was 34 months in all patients; it was significantly higher in the scc group as compared to the adenocarcinoma group (56 vs. 22 months) (p = 0.009). conclusion: ct-guided cryoablation can be a safe and effective treatment to control am secondary to nsclc.